Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Angiogenesis
Erschienen in: Angiogenesis 2/2016

22.02.2016 | Original Paper

Tumor vasculogenic mimicry predicts poor prognosis in cancer patients: a meta-analysis

verfasst von: J. P. Yang, Y. D. Liao, D. M. Mai, P. Xie, Y. Y. Qiang, L. S. Zheng, M. Y. Wang, Y. Mei, D. F. Meng, L. Xu, L. Cao, Q. Yang, X. X. Yang, W. B. Wang, L. X. Peng, B. J. Huang, C. N. Qian

Erschienen in: Angiogenesis | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Vasculogenic mimicry (VM) is the formation of vascular channels by tumor cells or tumor cell-derived, trans-differentiated cells in highly aggressive, solid tumors. However, the disease features and prognostic value of VM for overall survival of cancer patients remain controversial.

Method

To systematically investigate the roles of VM in cancer progression and its prognostic values, we performed a meta-analysis based on 36 studies (33 eligible articles) including 3609 patients. The pooled hazard ratios (HRs) with 95 % confidence intervals (95 % CIs) were used to assess the relationship between VM and overall survival in cancer patients.

Results

Vasculogenic mimicry was significantly associated with cancer differentiation, lymph node metastasis, distant metastasis, and TNM stage. The prognostic value of VM was significant in overall survival (HR 2.16; 95 % CI 1.98–2.38; P < 0.001). Analyses stratified by confounders, such as cancer type, ethnicity, VM detection methods, sample size, and Newcastle–Ottawa quality score, found similar significant results.

Conclusions

The presence of VM predicts poorer survival outcomes in cancer patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
3.
Liu J, Huang J, Yao WY, Ben QW, Chen DF et al (2012) The origins of vacularization in tumors. Front Biosci (Landmark Ed) 17:2559–2565CrossRef
4.
Qin L, Bromberg-White JL, Qian CN (2012) Opportunities and challenges in tumor angiogenesis research: back and forth between bench and bed. Adv Cancer Res 113:191–239CrossRefPubMed
5.
Qian CN (2013) Hijacking the vasculature in ccRCC–co-option, remodelling and angiogenesis. Nat Rev Urol 10:300–304CrossRefPubMed
6.
Qian CN, Tan MH, Yang JP, Cao Y (2016) Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation. Chin J Cancer 35:10CrossRefPubMedPubMedCentral
7.
Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM et al (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155:739–752CrossRefPubMedPubMedCentral
8.
9.
10.
Sun B, Zhang S, Zhao X, Zhang W, Hao X (2004) Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. Int J Oncol 25:1609–1614PubMed
11.
Zhang S, Li M, Zhang D, Xu S, Wang X et al (2009) Hypoxia influences linearly patterned programmed cell necrosis and tumor blood supply patterns formation in melanoma. Lab Invest 89:575–586CrossRefPubMed
12.
Van Beurden A, Schmitz RF, Van Dijk CM, Baeten CIM (2012) Periodic acid Schiff loops and blood lakes associated with metastasis in cutaneous melanoma. Melanoma Res 22:424–429CrossRefPubMed
13.
Dunleavey JM, Xiao L, Thompson J, Kim MM, Shields JM et al (2014) Vascular channels formed by subpopulations of PECAM1+ melanoma cells. Nat Commun 5:5200CrossRefPubMedPubMedCentral
14.
Sun B, Qie S, Zhang S, Sun T, Zhao X et al (2008) Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors. Hum Pathol 39:444–451CrossRefPubMed
15.
Li M, Gu Y, Zhang Z, Zhang S, Zhang D et al (2010) Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma. Pathol Oncol Res 16:259–266CrossRefPubMed
16.
Song YY, Sun LD, Liu ML, Liu ZL, Chen F et al (2014) STAT3, p-STAT3 and HIF-1alpha are associated with vasculogenic mimicry and impact on survival in gastric adenocarcinoma. Oncol Lett 8:431–437PubMedPubMedCentral
17.
Zhou L, Yu L, Feng ZZ, Gong XM, Cheng ZN et al (2015) Aberrant expression of markers of cancer stem cells in gastric adenocarcinoma and their relationship to vasculogenic mimicry. Asian Pac J Cancer Prev 16:4177–4183CrossRefPubMed
18.
Wang LGY, Zhang S, Sun B (2009) Pilot study and clinical prognosis significance of vasculogenic mimicry in leiomyosarcoma. Tianjin Med J 37:161
19.
Gao Y, Zhao XL, Gu Q, Wang JY, Zhang SW et al (2009) Correlation of vasculogenic mimicry with clinicopathologic features and prognosis of ovarian carcinoma. Zhonghua Bing Li Xue Za Zhi 38:585–589PubMed
20.
Yu L, Wu SW, Zhou L, Song WQ (2012) Correlation between bacterial L-form infection, expression of HIF-1alpha/MMP-9 and vasculogenic mimicry in epithelial ovarian cancer. Sheng Li Xue Bao 64:657–665PubMed
21.
Sun Q, Zou X, Zhang T, Shen J, Yin Y et al (2014) The role of miR-200a in vasculogenic mimicry and its clinical significance in ovarian cancer. Gynecol Oncol 132:730–738CrossRefPubMed
22.
Sun B, Zhang S, Zhang D, Du J, Guo H et al (2006) Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep 16:693–698PubMed
23.
Liu WB, Xu GL, Jia WD, Li JS, Ma JL et al (2011) Prognostic significance and mechanisms of patterned matrix vasculogenic mimicry in hepatocellular carcinoma. Med Oncol 28(Suppl 1):S228–S238CrossRefPubMed
24.
Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S et al (2002) Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer 99:821–828CrossRefPubMed
25.
Liu T, Sun B, Zhao X, Li Y, Gu Q et al (2014) OCT4 expression and vasculogenic mimicry formation positively correlate with poor prognosis in human breast cancer. Int J Mol Sci 15:19634–19649CrossRefPubMedPubMedCentral
26.
Liu SY, Chang LC, Pan LF, Hung YJ, Lee CH et al (2008) Clinicopathologic significance of tumor cell-lined vessel and microenvironment in oral squamous cell carcinoma. Oral Oncol 44:277–285CrossRefPubMed
27.
Wang W, Lin P, Han C, Cai W, Zhao X et al (2010) Vasculogenic mimicry contributes to lymph node metastasis of laryngeal squamous cell carcinoma. J Exp Clin Cancer Res 29:60CrossRefPubMedPubMedCentral
28.
Baeten CI, Hillen F, Pauwels P, de Bruine AP, Baeten CG (2009) Prognostic role of vasculogenic mimicry in colorectal cancer. Dis Colon Rectum 52:2028–2035CrossRefPubMed
29.
Liu Z, Sun B, Qi L, Li H, Gao J et al (2012) Zinc finger E-box binding homeobox 1 promotes vasculogenic mimicry in colorectal cancer through induction of epithelial-to-mesenchymal transition. Cancer Sci 103:813–820CrossRefPubMed
30.
31.
Wang SY, Ke YQ, Lu GH, Song ZH, Yu L et al (2013) Vasculogenic mimicry is a prognostic factor for postoperative survival in patients with glioblastoma. J Neurooncol 112:339–345CrossRefPubMed
32.
Cheng L, Huang Z, Zhou W, Wu Q, Donnola S et al (2013) Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153:139–152CrossRefPubMedPubMedCentral
33.
Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE et al (2010) Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468:829–833CrossRefPubMed
34.
Wu S, Yu L, Cheng Z, Song W, Zhou L et al (2012) Expression of maspin in non-small cell lung cancer and its relationship to vasculogenic mimicry. J Huazhong Univ Sci Technol Med Sci 32:346–352CrossRefPubMed
35.
Li Y, Sun B, Zhao X, Zhang D, Wang X et al (2015) Subpopulations of uPAR+ contribute to vasculogenic mimicry and metastasis in large cell lung cancer. Exp Mol Pathol 98:136–144CrossRefPubMed
36.
Wang X, Wang L, Gu Y, Zhang S, Zhao X et al (2009) Vasculogenic mimicry in testicular germ cell malignant tumor and its significance for prognosis. Chin J Clin Oncol 36:78–82
37.
Sun W, Shen ZY, Zhang H, Fan YZ, Zhang WZ et al (2012) Overexpression of HIF-1alpha in primary gallbladder carcinoma and its relation to vasculogenic mimicry and unfavourable prognosis. Oncol Rep 27:1990–2002PubMed
38.
Liu R, Yang K, Meng C, Zhang Z, Xu Y (2012) Vasculogenic mimicry is a marker of poor prognosis in prostate cancer. Cancer Biol Ther 13:527–533CrossRefPubMed
39.
Chai DM, Bao ZQ, Hu JG, Ma L, Feng ZZ et al (2013) Vasculogenic mimicry and aberrant expression of HIF-lalpha/E-cad are associated with worse prognosis of esophageal squamous cell carcinoma. J Huazhong Univ Sci Technol Med Sci 33:385–391CrossRefPubMed
40.
Zhang Y, Sun B, Zhao X, Liu Z, Wang X et al (2013) Clinical significances and prognostic value of cancer stem-like cells markers and vasculogenic mimicry in renal cell carcinoma. J Surg Oncol 108:414–419CrossRefPubMed
41.
Ren K, Yao N, Wang G, Tian L, Ma J et al (2014) Vasculogenic mimicry: a new prognostic sign of human osteosarcoma. Hum Pathol 45:2120–2129CrossRefPubMed
42.
Zhang X, Liu C, Luo L, Cai X (2013) Vasculogenic mimicry in tongue squamous cell carcinoma. Nan Fang Yi Ke Da Xue Xue Bao 33:593–597PubMed
43.
Hillen F, Baeten CI, van de Winkel A, Creytens D, van der Schaft DW et al (2008) Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma. Cancer Immunol Immunother 57:97–106CrossRefPubMed
44.
Jang TL, Bekelman JE, Liu Y, Bach PB, Basch EM et al (2010) Physician visits prior to treatment for clinically localized prostate cancer. Arch Int Med 170:440–450CrossRef
45.
Knobloch K, Yoon U, Vogt PM (2011) Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg 39:91–92CrossRefPubMed
46.
Panic N, Leoncini E, de Belvis G, Ricciardi W, Boccia S (2013) Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. PLoS ONE 8:e83138CrossRefPubMedPubMedCentral
47.
Sun B, Zhang S, Ni C (2005) The clinical significance study of vasculogenetic mimicry in 337 cases of bi-directional differential malignant tumors. Chin J Clin Oncol 32:64–67
48.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12CrossRefPubMed
49.
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed
50.
Whitehead A, Whitehead J (1991) A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 10:1665–1677CrossRefPubMed
51.
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRefPubMed
52.
Galbraith RF (1988) A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 7:889–894CrossRefPubMed
53.
Patsopoulos NA, Evangelou E, Ioannidis JP (2008) Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol 37:1148–1157CrossRefPubMed
54.
Mullen B, Muellerleile P, Bryant B (2001) Cumulative meta-analysis: a consideration of indicators of sufficiency and stability. Pers Soc Psychol Bull 27:1450–1462CrossRef
55.
Soeken KL, Sripusanapan A (2003) Assessing publication bias in meta-analysis. Nurs Res 52:57–60CrossRefPubMed
56.
57.
Qi H, Sun B, Zhao X, Du J, Gu Q et al (2014) Wnt5a promotes vasculogenic mimicry and epithelial-mesenchymal transition via protein kinase Calpha in epithelial ovarian cancer. Oncol Rep 32:771–779PubMed
58.
59.
Silvan U, Diez-Torre A, Bonilla Z, Moreno P, Diaz-Nunez M et al (2015) Vasculogenesis and angiogenesis in nonseminomatous testicular germ cell tumors. Urol Oncol 33(268):e217–e268
60.
61.
Qing YL, Sha TH, Ji FY, Qin HK, Jun CX et al (2009) Angiogenesis, vasculogenesis, and vasculogenic mimicry in ovarian cancer. Int J Gynecol Obstet 107:S242CrossRef
62.
Pezzella F, Harris AL (2014) When cancer co-opts the vasculature. N Engl J Med 370:2146–2147CrossRefPubMed
63.
Seftor RE, Hess AR, Seftor EA, Kirschmann DA, Hardy KM et al (2012) Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am J Pathol 181:1115–1125CrossRefPubMed
64.
Cao Z, Bao M, Miele L, Sarkar FH, Wang Z et al (2013) Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur J Cancer 49:3914–3923CrossRefPubMed
65.
Wagenblast E, Soto M, Gutierrez-Angel S, Hartl CA, Gable AL et al (2015) A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature 520:358–362CrossRefPubMedPubMedCentral
66.
Yao XH, Ping YF, Bian XW (2011) Contribution of cancer stem cells to tumor vasculogenic mimicry. Protein Cell 2:266–272CrossRefPubMed
67.
Vartanian A, Gatsina G, Grigorieva I, Solomko E, Dombrovsky V et al (2013) The involvement of Notch signaling in melanoma vasculogenic mimicry. Clin Exp Med 13:201–209CrossRefPubMed
68.
McAllister JC, Zhan Q, Weishaupt C, Hsu MY, Murphy GF (2010) The embryonic morphogen, Nodal, is associated with channel-like structures in human malignant melanoma xenografts. J Cutan Pathol 37(Suppl 1):19–25CrossRefPubMedPubMedCentral
69.
Tang N, Shi H, Zhang J (2013) HIF-1alpha induces expression of VE-cadherin and modulates vasculogenic mimicry in ESCC cells. J Gastroenterol Hepatol 28:863
70.
Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor REB et al (2006) VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther 5:228–233CrossRefPubMed
71.
Wang W, Lin P, Sun B, Zhang S, Cai W et al (2014) Epithelial-mesenchymal transition regulated by EphA2 contributes to vasculogenic mimicry formation of head and neck squamous cell carcinoma. Biomed Res Int 2014:803914PubMedPubMedCentral
72.
Margaryan NV, Strizzi L, Abbott DE, Seftor EA, Rao MS et al (2009) EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther 8:275–284CrossRef
73.
Lu XS, Sun W, Ge CY, Zhang WZ, Fan YZ (2013) Contribution of the PI3 K/MMPs/Ln-5gamma2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas. Int J Oncol 42:2103–2115PubMed
74.
Shi R, Jin HL, Zhang HJ (2011) Effect of RNA interference targeting for HIF-1(alpha) on vasculogenic mimicry in esophageal squamous cell carcinoma. Gastroenterology 140:S827
75.
Comito G, Calvani M, Giannoni E, Bianchini F, Calorini L et al (2011) HIF-1alpha stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. Free Radic Biol Med 51:893–904CrossRefPubMed
76.
Du J, Sun B, Zhao X, Gu Q, Dong X et al (2014) Hypoxia promotes vasculogenic mimicry formation by inducing epithelial-mesenchymal transition in ovarian carcinoma. Gynecol Oncol 133:575–583CrossRefPubMed
77.
Osinsky S, Zavelevich M, Vaupel P (2009) Tumor hypoxia and malignant progression. Exp Oncol 31:80–86PubMed
78.
Sun B, Zhang D, Zhang S, Zhang W, Guo H et al (2007) Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett 249:188–197CrossRefPubMed
Metadaten
Titel
Tumor vasculogenic mimicry predicts poor prognosis in cancer patients: a meta-analysis
verfasst von
J. P. Yang
Y. D. Liao
D. M. Mai
P. Xie
Y. Y. Qiang
L. S. Zheng
M. Y. Wang
Y. Mei
D. F. Meng
L. Xu
L. Cao
Q. Yang
X. X. Yang
W. B. Wang
L. X. Peng
B. J. Huang
C. N. Qian
Publikationsdatum
22.02.2016
Verlag
Springer Netherlands
Erschienen in
Angiogenesis / Ausgabe 2/2016
Print ISSN: 0969-6970
Elektronische ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-016-9500-2

Weitere Artikel der Ausgabe 2/2016

Angiogenesis 2/2016 Zur Ausgabe

Review Paper

Bone marrow-derived cells in ocular neovascularization: contribution and mechanisms

Original Paper

Suppression of vascular network formation by chronic hypoxia and prolyl-hydroxylase 2 (phd2) deficiency during vertebrate development

Original Paper

The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth

Original Paper

In vitro modeling of endothelial interaction with macrophages and pericytes demonstrates Notch signaling function in the vascular microenvironment

Brief Communication

In situ validation of VEGFR-2 and α v ß 3 integrin as targets for breast lesion characterization

Original Paper

Rasip1 is essential to blood vessel stability and angiogenic blood vessel growth

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise